Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: A study of 59 cases

PLoS ONE

Volumn 4, Issue 7, 2009, Pages

  Canioni, Danielle ^a   Deau Fischer, Bénédicte ^a   Taupin, Pierre ^a   Ribrag, Vincent ^b   Delarue, Richard ^a   Bosq, Jacques ^b   Rubio, Marie Thérèse ^a   Roux, Damien ^a   Vasiliu, Viorel ^a   Varet, Bruno ^a   Brousse, Nicole ^a   Hermine, Olivier ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; KI 67 ANTIGEN; PREDNISONE; PROCARBAZINE; PROTEIN; PROTEIN BCL 2; PROTEIN TIA 1; STEM CELL FACTOR; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; TUMOR MARKER;

ADULT; ARTICLE; CANCER RELAPSE; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MAST CELL; MICROENVIRONMENT; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; HODGKIN DISEASE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67749106603     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006341     Document Type: Article

References (46)

1. Montalban C, Garcia JF, Abraira V, Gonzalez-Camacho L, Morente MM, et al. (2004) Spanish Hodgkin's Lymphoma Study Group. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 9: 1664-73.
2. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM (2003) Hodgkin's Lymphoma: biology and treatment strategies for Primary Refractory and Relapsed Disease. Hematology Am Soc Hematol Program 1: 225-247. Review.
3. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, et al. (2005) Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 10: 943-51.
4. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, et al. (2005) A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 6: 557-66.
5. Josting A, Nogova L, Franklin J, Glossmann JP, Eich HT, et al. (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 7: 1522-29.
6. Josting A, Rueffer U, Franfklin J, Sieber M, Diahl V, et al. (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96: 1280-1286.
7. Sup SJ, Alemany CA, Pohlman B, Elson P, Malhi S, et al. (2005) Expression of bcl2 in Classical Hodgkin's Lymphoma: an independent predictor of poor outcome. J Clin Oncol 23: 3773-79.
8. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's disease. New England J Med 339: 1506-1514.
9. Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, et al. (2002) The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 9: 1370-7.
10. Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, et al. (2003) Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 7: 673-9.
11. Moskowitz C (2004) An update on the management of relapsed and primary refractory Hodgkin's disease. Semin Oncol 4: 54-9.
12. Lavoie J, Connors J, Philips G, Reece D, Barnette M, et al. (2005) High dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473-78.
13. Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, et al. (2003) High dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 6: 555-559.
14. Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, et al. (1998) Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 91: 3011-3016.
15. Reynolds GM, Billingham LJ, Gray LJ, Flavell JR, Najafipour S, et al. (2002) Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of B symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol 118: 195-201.
16. Glimelius I, Edstrom A, Amini RM, Fischer M, Nilsson G, et al. (2006) IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol 4: 278-283.
17. Smolewski P, Niewiadowska H, Blonski JZ, Robak T, Krykowski E (1998) Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: prognostic significance in Hodgkin' disease. Neoplasma 45: 140-147.
18. Spector N, Milito CB, Biasoli I, Luiz RR, Pulcheri W, et al. (2005) The prognostic value of the expression of bcl2, p53 and LMP1 in patients with Hodgkin's lymphoma. Leuk Lymphoma 9: 1301-1306.
19. Molin D (2004) Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Ups J Med Sci 3: 179-228.
20. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, et al. (1993) Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advances Hodgkin's disease and with B symptoms. Cancer Res 53: 2118-2122.
21. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, et al. (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11: 1467-73.
22. Alvaro-Naranjo T, Lejeune M, Salvado-Usach MT, Bosch-Princep R, Reverter-Branchat G, et al. (2005) Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue micro-array study in a large retrospective cohort of 267 patients. Leuk Lymphoma 11: 1581-1591.
23. Marshall N, Christie L, Munro L, Cullingan D, Johnston P, et al. (2004) Immunosuppressive regulatory T-cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103: 1755-62.
24. Fischer M, Juremalm M, Olsson N, Backilin C, Sundstrom C, et al. (2003) Expression of CCL5/rantes by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymhpomatous tissue. Int J Cancer 107: 197-201.
25. Dimitriadou V, Koutsilieris M (1997) Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res 17: 1541-1549.
26. Kuppers R (2002) Molecular biology of Hodgkin's lymphoma. Adv Cancer Res 84: 277-312.
27. Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, et al. (2000) Hodgkin and Reed Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95: 1443-1450.
28. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, et al. (2003) Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. pp 101-168.
29. Rajewsky K, Kanzler H, Hansmann ML, Kuppers (1997) Normal and malignant B-cell development with special reference to Hodgkin's disease. Ann Oncol 8: 79-81.
30. Kashkar H, Kronke M, Jurgensmeier JM (2002) Defective Bax activation in Hodgkin B-cell lines confers resistance to staurosporine-induced apoptosis. Cell Death Differ 7: 750-7.
31. Miyashita T, Reed JC (1993) Bcl2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157.
32. Brink AA, Oudejans JJ, van den Brule AJ, Kluin PM, Horstman A, et al. (1998) Low p53 and high bcl2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Mod Pathol 11: 376-383.
33. Tzankov A, Krugmann J, Fend F, Fischofer M, Greil R, et al. (2003) Prognostic significance of CD20 expression in classical Hodgkin lymhoma: a clinicopathological study of 119 cases. Clin Cancer Res 9: 1381-86.
34. Molot RJ, Mendenhall NP, Barre DM, Braylan RC (1994) The clinical relevance of L26, a B-cell - specific antibody in Hodgkin's disease. Am J Clin Oncol 17: 185-188.
35. Donnelly GB, Filippa D, Moskowitz CH, Portlock CS (1999) Increased treatment failure in patients with CD20 positive classic Hodgkin disease (HD). Blood 94: 598a.
36. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, et al. (2002) CD20 expression in Hodgkin disease and Reed Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 20: 1278-1287.
37. Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, et al. (2004) Adverse prognostic significance of CD20 postivie Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol 125: 701-708.
38. Dilman RO (2001) Monoclonal antibody therapy for lymphoma. Cancer 9: 71-80.
39. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, et al. (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 10: 949-954.
40. Foran JM, Rohatiner AZ, Cunningham D, Popescus RA, Solal-Celigny P, et al. (2000) European phase II study of rituximab (chimeric and anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small-B cell lymphocytic lymphoma. J Clin Oncol 18: 317-324.
41. Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, et al. (1997) Adverse clinical outcome of Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index and absence of Epstein Barr virus-latent membrane protein 1 expression. Blood 90: 2429-2436.
42. Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, et al. (2001) Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97: 250-255.
43. Molin D, Edstrom A, Glimelius I, Glimelius B, Nilsson G, et al. (2002) Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Hematol 119: 122-124.
44. Glimelius I, Edström A, Fischer M, Nilsson G, Sunström C, et al. (2005) Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 19: 2360-2362.
45. Akin C, Metcalfe DD (2004) The biology of c-kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 114: 13-19.
46. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, et al. (1996) Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 88: 3299-3305.